Nanjing Vazyme Biotech (688105.SS) Earnings Analysis

Nanjing Vazyme Biotech (688105.SS) next reports earnings on 2026-08-29. Trailing P/E -516.46.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 688105.SS next report earnings?

Next earnings date2026-08-29
Consensus EPS estimaten/a
Revenue estimaten/a

688105.SS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-220.01 CNYn/an/an/a
2026-02-26-0.0556 CNYn/an/an/a
2025-10-300.0095 CNYn/an/an/a
2025-08-290.0033 CNYn/an/an/a
2025-04-280.005 CNYn/an/an/a
2025-02-28-0.1 CNYn/an/an/a
2024-10-310.0071 CNYn/an/an/a
2024-08-280.0382 CNYn/an/an/a

688105.SS valuation and analyst view

Trailing P/E-516.46
Trailing EPS-0.03515 CNY
Price / book1.86
Dividend yield2.95%
Market cap8.73B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Nanjing Vazyme Biotech (688105.SS)'s next earnings date?

Nanjing Vazyme Biotech is next scheduled to report on 2026-08-29.

Did 688105.SS beat earnings last quarter?

Consensus estimate data was not available for 688105.SS's 2026-04-22 report.

What is 688105.SS's current P/E ratio and EPS?

688105.SS trades at a trailing P/E of -516.46 on trailing EPS of -0.03514980629187873 CNY.

What do analysts rate 688105.SS?

688105.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.